Amgen Gains Phase II Phosphate Binder With Acquisition of Ilypsa
This article was originally published in The Pink Sheet Daily
Executive Summary
Ilypsa’s lead candidate, ILY1001, for treatment of hyperphosphatemia in chronic kidney disease, complements Amgen’s anemia agents.